Histone deacetylase inhibitors (HDACIs) induce growth arrest and apoptosis in cancer cells. In addition to their intrinsic anticancer properties, HDACIs modulate cellular responses to ionizing radiation (IR). We examined the molecular mechanism(s) associated with the radiosensitizing effects of HDACIs in human lung cancer cells. Methods: Lung cancer cells were pretreated with the appropriate concentrations of suberoylanilide hydroxamic acid or trichostatin A. After 2 hours, cells were irradiated with various doses of ␥-IR, and then we performed 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, fluorescence-activated cell sorting analysis, clonogenic assay, and Western blotting to detect cell viability or apoptosis and changes of specific proteins expression levels. Results: In this study, we showed that HDACIs (including suberoylanilide hydroxamic acid and trichostatin A) and IR synergistically trigger cell death in human non-small cell lung cancer cells. Cell viability and clonogenic survival were markedly decreased in cultures cotreated with HDACIs and IR. Interestingly, p53 acetylation at lysine 382 was significantly increased, and c-myc expression simultaneously down-regulated in cotreated cells. Radiosensitization by HDACIs was inhibited on transfection with small interfering RNA against p53 and c-myc overexpression, supporting the involvement of p53 and c-myc in this process. Furthermore, c-myc downregulation and apoptotic cell death coinduced by IR and HDACI were suppressed in cells transfected with mutant K382R p53 and C135Y p53 displaying loss of acetylation at lysine 382 and DNAbinding activity, respectively. Conclusions: Our results collectively demonstrate that the degree of radiosensitization by HDACIs is influenced by acetyl p53-mediated c-myc down-regulation.
T he histone acetylation status is determined by the opposing actions of histone acetyl transferase (HAT) and histone deacetylase (HDAC), which lead to alterations in chromatin structure, and consequently, regulation of gene expression. The activities of these enzymes are disrupted in several cancers. 1 In particular, aberrant HDAC activity results in the transcriptional repression of tumor suppressor genes, which is a common event in tumor formation. Given this molecular finding, HDACIs are considered promising therapeutic agents for cancer treatment. In a number of in vitro and in vivo experimental models, HDACIs induce diverse biological responses in cancer cells, including apoptosis, cell cycle arrest, and differentiation. These compounds additionally exhibit lower toxicity in normal cells and tissues, because aberrant acetylation is a characteristic of neoplastic cells. 2, 3 Although the molecular events underlying the biological effects of HDACIs remain to be fully elucidated, recent studies have demonstrated a direct link between induction of apoptosis in cancer cells and the therapeutic efficacy of these compounds. In addition, combinations of HDACIs with other chemotherapeutic drugs and ionizing radiation (IR) have been shown to exert strong synergistic effects in several cancer cells, compared with single agents. 4 -8 The molecular mechanism(s) associated with the radiosensitizing effects of HDACIs in a broad array of cancer cells remain to be clarified.
In addition to histones, p53 serves as a substrate of HAT and HDAC in vitro and in vivo. 9 -12 p53 is a sequence-specific DNA-binding transcription factor that exerts antiproliferative effects, including apoptosis and growth arrest, in response to various stress factors. Posttranslational modifications, including phosphorylation and acetylation, play important roles in the stabilization and activation of p53 in response to stress signals, such as DNA damage. 13 HDACIs impede deacetylation and stabilize the acetylated isoforms of p53. 14, 15 These results suggest that stabilization of acetylated p53 by these compounds is involved in modulation of the expression levels of different subsets of genes.
In this study, we explored the potential therapeutic value of a combination of HDACIs, including suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), with IR in human lung cancer cells. Moreover, the potential cellular mechanisms underlying enhanced antitumor activity were examined. Our data show that site-specific stabilization of acetylated p53 results in c-myc down-regulation. Experiments performed to evaluate the significance of c-myc repression by p53 demonstrated that ectopic c-myc expression interferes with the combined therapeutic effects of HDACIs and IR. On the basis of these results, we propose that HDACIs sensitize lung cancer cells to IR through acetyl p53-mediated c-myc down-regulation.
MATERIALS AND METHODS

Cell Cultures and Reagents
A549 and H1299 human non-small cell lung cancer cells were purchased from the American Type Culture Collection (Manassas, VA) and grown in the recommended growth medium (Invitrogen, Carlsbad, CA). SAHA and TSA were purchased from ALEXIS Corporation (Switzerland) and Sigma-Aldrich (St. Louis, MO), respectively. Antibodies against acetyl-p53 (Lys 382), acetyl-p53 (Lys 373), phosphop53 (Ser 15), and phospho-p53 (Ser 46) were acquired from Cell Signaling Technology (Beverly, MA). Antip21 and antip53 antibodies were purchased from BD Biosciences Pharmingen (San Diego, CA) and Novocastra Laboratory. Ltd. (United Kingdom), respectively, while those against c-myc and ␤-actin were acquired from Santa Cruz Biotechnology (Santa Cruz, CA). Negative control and p53-specific small interfering RNA (siRNA) were purchased from Ambion (Austin, TX).
Treatment with HDACIs and IR
Cells were pretreated with SAHA (2.5M) or TSA (0.5M). After 2 hours, cells were irradiated with various doses of ␥-IR using a 137 Cs ␥-ray source (Atomic Energy of Canada Ltd., Canada).
Measurement of Cell Viability
Cell viability was determined by measuring the mitochondrial conversion of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) to a colored product. Cells were treated with the specified drugs, and the medium was exchanged with serum-free medium containing 1 mM MTT. After 4 hours of incubation at 37°C, cells were solubilized in DMSO. The amount of formazan, the converted form of MTT, was determined by measuring absorbance at 570 nm.
Analysis of Cellular Apoptosis
Apoptosis was determined using an annexin V-fluorescein isothiocyanate/propidium iodide (PI) kit (BD Pharmingen, San Jose, CA). Briefly, cells were washed with cold phosphate-buffered saline and resuspended in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl 2 ) at a concentration of 1 ϫ 10 6 cells/ml. Cells were incubated with 5 l of Annexin V-fluorescein isothiocyanate and PI and analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose, CA).
Measurement of Mitochondrial Transmembrane Potential
Loss of mitochondrial transmembrane potential was measured using an ApoAlert mitochondrial membrane sensor kit (Clontech, Palo Alto, CA), according to the manufacturer's instructions. Briefly, after drug treatment, cells were incubated with Mitosensor for 15 minutes at 37°C. After centrifugation at 1700 g for 7 minutes, cells were resuspended in washing buffer and analyzed with the fluorescence channel by flow cytometry. Results are presented as mean values of the stained cell histogram.
Clonogenic Assay
Cells were seeded at a concentration of 200 cells per 60-mm dish and pretreated with 0.5 M or 1 M SAHA. After 2 hours, cells were irradiated with various doses (1 or 2 Gy) of ␥-IR. After culturing for 18 days, colonies were stained with the Diff Quik kit (Sysmex, Japan), and the number of colonies greater than 2 mm in diameter was counted (Ͼ300 colonies per well is a cutoff number of colonies required for each treatment for a valid experiment). The relative surviving fraction was calculated by dividing the number of colonies of treated cells by that of the control.
Western Blotting
Cells were harvested and lysed in radioimmunoprecipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate supplemented with a protease inhibitor cocktail; Roche, Mannheim, Germany). Lysate concentrations were determined with the Bradford assay. Equal amounts of protein (20 -50 g) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Membranes were blocked with 3% skim milk in Tris-buffered saline for 1 hour and incubated overnight with the relevant primary antibodies (1000:1). Then, membranes were incubated with horseradish peroxidase-conjugated secondary antibody (3000:1) for 1 hour. Immunoreactive proteins were visualized with the enhanced chemiluminescence reagent (Amersham Biosciences, Little Chalfont, United Kingdom).
Site-Directed Mutagenesis
The p53 mutant (C135Y and K382R) constructs were generated using the Stratagene site-directed mutagenesis kit (La Jolla, CA). Wild-type p53 expression vector (Invitrogen) was used as the template. K382 of wild-type p53 was mutated to arginine using the following primer sequences: p53-K382R-up, 5Ј-CT ACC TCC CGC CAT AAA AG(A)A CTC ATG TTC AAG A-3Ј and p53-K382R-down, 5Ј-T CTT GAA CAT GAG TC(T)T TTT ATG GCG GGA GGT AG-3Ј. 13 For substitution of C135 of p53 with tyrosine, the following primer sequences were used: p53-C135Y-up, 5Ј-C CTC AAC AAG ATG TTT TA(G)C CAA CTG GCC AAG ACC-3Ј and p53-C135Y-down, 5Ј-GGT CTT GGC CAG TTG GT(C)A AAA CAT CTT GTT GAG G-3Ј. The replaced nucleotides within the sequences are italicized, and the original nucleotides are presented in parentheses. The p53 6KR mutant plasmids and primers were synthesized by Cosmogene Tech (Seoul, South Korea).
Transfections
The c-myc-expressing plasmid was a kind gift from Dr. Younghun Han (KIRAMS, Korea). A549 cells were transfected with 0.2 to 0.6 g plasmid or 60 nM siRNA, using Lipofectamine 2000 (Invitrogen), in 1 ml of serum-free medium for 4 hours at 37°C in a CO 2 incubator, according to the manufacturer's recommendations. Next, 2 ml of 10% fetal bovine serum was added, followed by incubation for an additional 3 hours. After transfection, cells were subjected to apoptosis analysis, as described earlier.
RESULTS
Radiosensitization Effects of HDACIs
The effects of HDACIs, including SAHA and TSA, in combination with IR, were examined in the human non-small cell lung cancer cell line, A549. The MTT assay was used to determine cell viability ( Figure 1A) . Our results showed that a combination of HDACIs and IR decreased the viability of cells more significantly than either agent alone. Cell death analysis was additionally performed on cells treated with HDACIs, IR, or both for 24 hours. Annexin V/PI staining experiments revealed that the HDACI/IR combination synergistically induced cell death ( Figure 1B) . Consistent with Annexin V/PI staining data, HDACIs and IR exerted similar synergistic effects on loss of mitochondrial transmembrane potential. These findings clearly indicate that a combination of HDACIs and IR triggers a higher degree of apoptosis in cells than either agent alone. Next, A549 cells were exposed to IR in the presence and absence of the HDACI, SAHA, and clono- 
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genic survival was determined. The radiation survival curve showed that SAHA treatment sensitized the cells to IR ( Figure 1C) . Notably, the radiation survival curve of cells treated with 0.5 M SAHA diverged from that of cells treated with 1 M SAHA. This effect was more evident at higher radiation doses.
p53 Is Up-Regulated by the Combination of HDACIs and IR
To explore the molecular mechanisms underlying the combined effects of HDACIs and IR, we evaluated the p53, phosphorylated p53 (phospho-p53, Ser 15, and 46), and acetylated p53 (acetyl-p53, Lys 373, and 382) levels, after cotreatment with HDACIs and IR or single agents. As shown in Figure 2 , p53 and phospho-p53 levels were markedly increased in cells treated with IR in both the presence and absence of HDACIs. Interestingly, the HDACI/IR combination further enhanced acetyl-p53 (Lys 382) and c-myc protein levels, relative to either agent alone. In contrast, the level of p53 acetylated at Lys 373 remained unchanged. The p21 Waf1 protein was up-regulated to a similar extent in cells treated with the HDACI/IR combination or either agent alone. Our data suggest that HDACIs and IR act concertedly to modulate the acetyl-p53 level to a greater extent, compared with either agent alone.
Effects of p53 Down-Regulation on Cell Viability
To further investigate the association between p53 and the radiosensitizing effect of HDACIs, we examined the effects of p53 siRNA in cells cotreated with SAHA and IR. Transfection of A549 cells with p53-selective siRNA led to a marked reduction in the p53 and p21 protein levels. Knockdown of p53 with siRNA significantly attenuated the radiosensitization effect of SAHA, supporting the involvement of p53 in this process ( Figure 3A) . Interestingly, c-myc expression was down-regulated on SAHA and IR cotreatment and significantly recovered in the presence of p53 siRNA. Furthermore, transfection of H1299 p53-null cells with a plasmid expressing the p53 C135Y mutant led to recovery from cell death and c-myc down-regulation induced by the combination of HDACIs and IR ( Figure 3B ). The p53 C135Y expression plasmid encoding a dominant-negative mutant can no longer interact with p53 binding sites because of a conformational change induced by mutation of cysteine 135 to tyrosine. 16, 17 These results suggest that p53 plays an important role in the radiosensitization effect of HDACIs and acts upstream of c-myc expression.
Effects of c-Myc Overexpression on Cell Viability
Because the combination of HDACIs and IR induced p53-dependent repression of c-myc, we investigated whether c-myc expression affected cell death in cotreated cultures. After transient transfection with the pcDNA3 c-myc vector, A549 cells were cotreated with HDACIs and IR (Figure 4) . Overexpression of c-myc partially blocked cell death induced by HDACIs and IR. On the basis of these findings, we propose that c-myc repression is involved in the radiosensitizing effect of HDACIs.
Induction of p53 Acetylation-Mediated c-myc Repression by the Combination of HDACIs and IR
To confirm that c-myc-induced repression in cell death induced by the combination of HDACIs and IR is regulated by p53 acetylation, we performed experiments with the p53-null lung cancer cell line, H1299. As shown in Figure 5A , the c-myc expression level was not altered by HDACIs alone or in combination with IR. Moreover, we did not observe a radiosensitizing cell death effect on H1299 cells. To further identify the specific lysine acetylation sites of p53 critical for c-myc repression, plasmids expressing wild-type p53 and p53 mutated at lysines 320, 370, 372, 373, 381, and 382 to arginine (6KR) or lysine 382 to arginine (K382R) were transfected into H1299 cells. H1299 expressing the K382R and 6KR p53 mutants recovered from cell death induced by HDACIs and IR to similar extents ( Figure 5B ). In keeping with this finding, c-myc down-regulation induced by the combination of HDACIs and IR was rescued on mutation of p53. These data imply that repression of c-myc is accompanied by increased p53 acetylation, particularly at lysine 382, leading to the combined radiosensitizing cell death effect of HDACIs and IR.
DISCUSSION
HDACIs enhance the sensitivity of various cell lines to IR or chemotherapeutics. 4 -8 In this study, we showed that combinations of HDACIs (SAHA and TSA) and IR syner-FIGURE 2. Protein levels of acetyl-p53 (Lys 382) are upregulated and c-myc down-regulated synergistically in A549 cells cotreated with suberoylanilide hydroxamic acid (SAHA) or trichostatin A (TSA) and ionizing radiation (IR). Cells were treated for 24 hours as specified in Figure 1B . Western blotting was carried out, as described in Materials and Methods section. Equal protein loading was confirmed by Western blotting for ␤-actin. Immunoblots are representative of at least two independent experiments.
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gistically induced cell death through acetyl p53-mediated repression of c-myc expression. Low concentrations of HDACIs alone exerted a marginal effect on p53, including protein level, phosphorylation, and acetylation, but specifically potentiated p53 acetylation on cotreatment with IR. Stabilization of p53 induced by combined treatment with HDACI and IR may occur through acetylation. It is well known that specific HAT and HDAC enzymes modulate the acetylation status of p53. Because several lysine residues of the p53 C-terminal domain are also targets for mdm2-mediated ubiquitination, acetylation of these sites leads to an increase in the steady-state level of p53. 18, 19 Therefore, it is generally accepted that posttranslational modifications play an important role in the stabilization and activation of p53. A recent study additionally suggested that acetylation prevents down-regulation of p53 function by blocking the recruitment of mdm2 and mdmx to p53-responsive promoters. 20 p53 regulates the expression of a number of target genes that contribute to cellular responses. The tumor suppressor directly induces genes that promote apoptosis, such as p21, bax, puma, noxa, and fas. 21, 22 In addition, p53 suppresses genes that inhibit p53-induced apoptosis, such as bcl-2, survivin, and c-myc. 23, 24 Accordingly, we examined whether the p53-regulated genes, bcl-2, bax, p21, and puma, are involved in the radiosensitization effects of HDACIs. In our experiments, Puma and c-myc protein levels were altered on cotreatment with HDACIs and IR (Figure 2 ). Synergistic induction of apoptosis by HDACIs and IR was not affected on transfection of cells with siRNA against Puma (data not shown), suggesting that Puma is not the critical cause of cell death. Expression of c-myc protein was markedly decreased after treatment with HDACIs and IR and recovered on transfection with p53 siRNA (Figures 2 and 3 ). In addition, ectopic expression of c-myc led to a significant decrease in apoptotic cell death induced by HDACIs and IR (Figure 4) . These results indicate that c-myc expression is repressed through p53 activation and that this step plays an important role in apoptosis coinduced by HDACIs and IR.
c-Myc acts as a transcription activator or repressor that regulates proliferation, mitogenesis, differentiation, and programmed cell death. 23 A previous study showed that the c-Myc interaction partner, Miz-1, binds and activates transcription of the p21 WAF1/CIP1 promoter, leading to inhibition of cell cycle progression. 25 In addition, it is reported that TSA activates p21 expression through down-regulation of c-myc and release of c-myc repression from the p21 promoter in HeLa cells. 1 To further ascertain whether down-regulation of c-myc is mediated by p21, we examined the c-myc expres-sion levels in H1299 cells before and after combined treatment with HDACIs and IR. As shown in Figure 5 , the p21 level was up-regulated by SAHA alone and in combination with IR in p53-null cells, whereas the c-myc level remained unchanged. In addition, we observed no attenuation of the p21 level after treatment with both HDACIs and IR in the presence of specific siRNA against c-myc (data not shown). On the basis of these results, we conclude that p53-dependent repression of c-myc is not a consequence of p53-dependent p21 activation.
Selective acetylation of p53 triggers differential changes in gene expression. 26 To identify the specific site of p53 acetylation influencing c-myc repression on cotreatment with HDACIs and IR, we transfected plasmids expressing mutant p53 (6KR or K382R) into p53-null H1299 cells. Expression of c-myc expression was recovered on transfection of cotreated cells with the p53 K382R mutant, suggesting that repression of c-myc by p53 is mediated by acetylation at K382 ( Figure 5B ). Binding of p53 to the c-myc promoter may be decreased as a result of acetylation. Further studies are necessary to determine the mechanism by which p53 acetylated at K382 regulates c-myc expression, and whether other acetylation site(s) of p53 are involved in this process. In FIGURE 5. c-Myc protein levels are not altered in p53 mutant-transfected H1299 cells cotreated with histone deacetylase inhibitors and ionizing radiation (IR). Acetylation of p53 at K382 is required for down-regulation of c-myc. A, H1299 cells were treated for 24 hours as specified in Figure 1B and subjected to Western blot analysis. Equal protein loading was confirmed by Western blotting for ␤-actin. B, H1299 cells were transiently transfected with the control plasmid (pCMV) and plasmid encoding wild-type, K382R, or 6KR mutant p53 (p53, K382R, and 6KR, respectively), followed by treatment with 2.5 M suberoylanilide hydroxamic acid (SAHA) and 5Gy IR for 24 hours. After treatment with MTT, the viability of control cells was set at 100%, and survival relative to the control was calculated. Cells were lysed and subjected to Western blot analysis. Equal protein loading was confirmed by Western blotting for ␤-actin. **p Ͻ 0.01 versus p53 plasmid-transfected and IR/SAHA-treated groups. Each value represents means Ϯ SD of three independent experiments. Immunoblots are representative of at least two independent experiments. TSA, trichostatin A. conclusion, our data strongly suggest that radiosensitizing effect of HDACIs is mediated by c-myc repression dependent on p53 acetylation at K382.
